Safety and Pharmacology Study of VP 20629 (now called SHP622) in Adults With FA

Ages: 18-45

Locations: Children's Hospital of Philadephia (CHOP), Emory, University of South Florida, University of Iowa, UCLA

Details: This is a Phase 1 study sponsored by Shire (formerly initiated by ViroPharma) designed to evaluate dosage and safety of VP20629, a naturally occurring small molecular weight drug compound that can prevent oxidative stress to improve mitochondrial function. Participation in this study requires both outpatient and inpatient visits. Subjects in the second arm need to stay in the hospital for 10 days. In the second arm, subjects will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.

Specific information on inclusion and exclusion criteria is available here: www.clinicaltrials.gov/ct2/show/NCT01898884
 
Please call or email one of the sites below if you are interested in participating:
 

Children's Hospital of Philadelphia (CHOP), Philadelphia, PA
Principal Investigator: Dr. David Lynch
Coordinators:
Lauren Seyer from CHOP/ Tel.: (267) 426-9738; Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Debbie Foerster from CHOP/ Tel.: (267) 426-7584; Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
CHOP study ad: http://curefa.org/_pdf/VP20629ClinicalTrial.pdf

Emory University, Atlanta, GA
Principal Investigator: Dr. George Wilmot
Coordinator: Rebecca McMurray, *NOTE New Phone Number* Tel: 404-712-7013; Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Emory study ad: www.curefa.org/_pdf/EmoryTrialVP20629.pdf

University of South Florida, Tampa, FL
Principal Investigator: Dr. Theresa Zesiewicz
Coordinator: Kevin Allison, Tel: (813) 974-5909; email: This email address is being protected from spambots. You need JavaScript enabled to view it.

University of Iowa, Iowa City, IA
Principal Investigator: Dr. Kathy Mathews
Coordinator: Carrie Stephan, Tel: (319) 356-2673; email: This email address is being protected from spambots. You need JavaScript enabled to view it.

UCLA Medical Center, Los Angeles, CA
Principal Investigator: Dr. Susan Perlman
Coordinator: Brian Clemente, Tel: (310) 794-1225; email: This email address is being protected from spambots. You need JavaScript enabled to view it.
UCLA study ad: http://curefa.org/_pdf/UCLA-Trial-VP20629.pdf